Ranolazine in Hypertrophic Cardiomyopathy

Abstract

Ranolazine was introduced initially as an anti-anginal agent. Later anti-arrhythmic properties were highligted and a new classification included ranolazine as a Class Id antiarrhythmic agent. Preclinical studies, case reports and open labelled studies have shown the beneficial effects of ranolazine in hypertrophic cardiomyopathy. But a double blind placebo controlled trial failed to document symptomatic relief, though it showed lower incidence of ventricular premature complexes.